GH Guardant Health Inc

Price (delayed)

$126.02

Market cap

$12.77B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.77

Enterprise value

$13.17B

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health ...

Highlights
Guardant Health's revenue has increased by 26% YoY and by 9% from the previous quarter
The gross profit has grown by 24% YoY and by 9% from the previous quarter
Guardant Health's quick ratio has increased by 37% YoY but it has decreased by 8% from the previous quarter
The EPS has dropped by 195% year-on-year and by 12% since the previous quarter
GH's equity is down by 29% YoY and by 7% QoQ

Key stats

What are the main financial stats of GH
Market
Shares outstanding
101.3M
Market cap
$12.77B
Enterprise value
$13.17B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
16.17
Price to sales (P/S)
39.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.7
Earnings
Revenue
$323.65M
EBIT
-$372.09M
EBITDA
-$339.48M
Free cash flow
-$209.38M
Per share
EPS
-$3.77
Free cash flow per share
-$2.07
Book value per share
$7.79
Revenue per share
$3.2
TBVPS
$22.47
Balance sheet
Total assets
$2.29B
Total liabilities
$1.44B
Debt
$1.35B
Equity
$788.07M
Working capital
$1.79B
Liquidity
Debt to equity
1.71
Current ratio
19.57
Quick ratio
19.1
Net debt/EBITDA
-1.2
Margins
EBITDA margin
-104.9%
Gross margin
66.5%
Net margin
-117%
Operating margin
-114.6%
Efficiency
Return on assets
-18.5%
Return on equity
-37.6%
Return on invested capital
-17.4%
Return on capital employed
-16.9%
Return on sales
-115%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GH stock price

How has the Guardant Health stock price performed over time
Intraday
-1.85%
1 week
-2.43%
1 month
4.71%
1 year
12.72%
YTD
-2.22%
QTD
1.47%

Financial performance

How have Guardant Health's revenue and profit performed over time
Revenue
$323.65M
Gross profit
$215.38M
Operating income
-$370.92M
Net income
-$378.65M
Gross margin
66.5%
Net margin
-117%
GH's operating income has plunged by 179% YoY and by 13% from the previous quarter
The net margin has dropped by 151% year-on-year and by 3.8% since the previous quarter
The company's operating margin has shrunk by 122% YoY and by 4.1% QoQ
Guardant Health's revenue has increased by 26% YoY and by 9% from the previous quarter

Growth

What is Guardant Health's growth rate over time

Valuation

What is Guardant Health stock price valuation
P/E
N/A
P/B
16.17
P/S
39.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.7
The EPS has dropped by 195% year-on-year and by 12% since the previous quarter
GH's equity is down by 29% YoY and by 7% QoQ
The P/B is 22% more than the last 4 quarters average of 13.5
Guardant Health's revenue has increased by 26% YoY and by 9% from the previous quarter
The P/S is 9% below the last 4 quarters average of 43.9

Efficiency

How efficient is Guardant Health business performance
The ROE has plunged by 174% YoY and by 22% from the previous quarter
The return on sales has dropped by 146% year-on-year and by 3.9% since the previous quarter
GH's ROA has dropped by 59% year-on-year
Guardant Health's ROIC has decreased by 18% YoY but it has increased by 7% from the previous quarter

Dividends

What is GH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GH.

Financial health

How did Guardant Health financials performed over time
Guardant Health's total assets is 59% more than its total liabilities
Guardant Health's total assets has soared by 79% YoY but it has decreased by 2.3% from the previous quarter
Guardant Health's quick ratio has increased by 37% YoY but it has decreased by 8% from the previous quarter
The debt is 71% greater than the equity
GH's equity is down by 29% YoY and by 7% QoQ
GH's debt to equity is up by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.